Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomized trial
Open Access
- 1 January 1999
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 69 (1) , 99-104
- https://doi.org/10.1093/ajcn/69.1.99
Abstract
Background: An elevated plasma total homocysteine concentration is a risk factor for cardiovascular disease and neural tube defects. A high daily intake of supplemental folic acid is known to decrease total homocysteine concentrations. Objective: We studied the effect of low-dose folic acid administration (250 or 500 μg/d) for 4 wk on plasma total homocysteine concentrations and folate status. We also investigated whether total homocysteine concentrations and blood folate concentrations returned to baseline after an 8-wk washout period. Design: In this placebo-controlled study, 144 healthy women aged 18–40 y received 500 μg folic acid/d, 500 μg folic acid every second day (250 μg/d), or a placebo tablet with their habitual diet (mean dietary folate intake: 280 μg/d). Results: Administration of 250 and 500 μg folic acid/d for 4 wk significantly increased folate concentrations in plasma (P < 0.001) and red blood cells (P < 0.01). Total homocysteine concentrations decreased significantly (P < 0.001) in women (n = 50) who took 250 μg folic acid/d [mean (±SEM) deviation from baseline: −11.4 ± 1.98%] and in women (n = 45) who took 500μg folic acid/d (−21.8 ± 1.49%). Eight weeks after the end of the intervention period (week 12), plasma total homocysteine concentrations in the folic acid–supplemented groups had not returned to baseline (week 0). Conclusions: Doses of folic acid as low as 250 μg/d, on average, in addition to usual dietary intakes of folate significantly decreased plasma total homocysteine concentrations in healthy, young women. An 8-wk washout period was not sufficient for blood folate and plasma total homocysteine concentrations to return to baseline concentrations.Keywords
This publication has 28 references indexed in Scilit:
- Homocysteine metabolism in pregnancies complicated by neural-tube defectsThe Lancet, 1995
- Maternal hyperhomocysteinemia: A risk factor for neural-tube defects?Metabolism, 1994
- Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery diseaseThe American Journal of Clinical Nutrition, 1994
- Prevention of the First Occurrence of Neural-Tube Defects by Periconceptional Vitamin SupplementationNew England Journal of Medicine, 1992
- A randomised trial of low dose folic acid to prevent neural tube defects. The Irish Vitamin Study Group.Archives of Disease in Childhood, 1992
- Prevention of neural tube defects: Results of the Medical Research Council Vitamin StudyPublished by Elsevier ,1991
- Hyperhomocysteinemia: An Independent Risk Factor for Vascular DiseaseNew England Journal of Medicine, 1991
- Neural-Tube Defects and Derangement of Homocysteine MetabolismNew England Journal of Medicine, 1991
- Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects.BMJ, 1981
- POSSIBLE PREVENTION OF NEURAL-TUBE DEFECTS BY PERICONCEPTIONAL VITAMIN SUPPLEMENTATIONThe Lancet, 1980